Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 285
Last updated 2024-02-26
Summary
To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-01
- Primary Completion
- 2019-05-15
- Completion
- 2020-08-15
Countries
- China
Study Locations
More Related Trials
-
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612 ·Status: RECRUITING
-
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
NCT05572645 ·Status: COMPLETED
-
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2
-
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
NCT06711068 ·Status: RECRUITING
-
Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer
NCT04900311 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
NCT06341621 ·Status: RECRUITING ·Phase: PHASE3
-
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
NCT05263570 ·Status: RECRUITING
-
A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
NCT03989037 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer
NCT05149014 ·Status: COMPLETED
-
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
NCT04498793 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
NCT05191914 ·Status: UNKNOWN ·Phase: PHASE4
-
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
NCT04681287 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
NCT05491694 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298 ·Status: RECRUITING ·Phase: PHASE3
-
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369 ·Status: RECRUITING
-
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
NCT04385563 ·Status: UNKNOWN ·Phase: PHASE3
-
B002 in Patients With HER2-positive Breast Cancer
NCT04382352 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NCT06172322 ·Status: RECRUITING ·Phase: PHASE1
-
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
NCT04917900 ·Status: UNKNOWN ·Phase: PHASE2
-
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
NCT03695341 ·Status: COMPLETED
-
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
NCT07180160 ·Status: RECRUITING ·Phase: PHASE2